从代谢调控到器官保护：SGLT-2抑制剂联合策略的药理学整合

摘要：Li Y, Chen X, Zhang S, et al. Nationwide prevalence of chronic kidney disease in China, 2018–2019: a crosssectional survey. Lancet

参考文献

[1] Li Y, Chen X, Zhang S, et al. Nationwide prevalence of chronic kidney disease in China, 2018–2019: a crosssectional survey. Lancet Reg Health West Pac. 2023;39:100947.

[2] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(1 Suppl):S1S150.

[3] 中华预防医学会肾脏病预防与控制专业委员会. 中国慢性肾脏病早期评价与管理指南（2023版）. 中华预防医学杂志. 2023;57(12):14611488.

[4] Ji L, Liu M, Hu Y, et al. Dapagliflozin as monotherapy in drugnaive Asian patients with type 2 diabetes mellitus: a randomized, doubleblind, placebocontrolled phase III study. Clin Ther. 2014;36(2):194207.

[5] Xu X, Kohan DE, Wang D, et al. The hallmarks of mitochondrial dysfunction in chronic kidney disease. Biomedicines. 2024;12(1):45.

[6] Brown DA, Perry JB, Allen ME, et al. Mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2021;18(9):651667.

[7] D’Elia T, Weinrauch LA. Lipotoxicity and maladaptive cardiovascularrenalmetabolic remodeling: mechanisms and therapeutic prospects. Biomedicines. 2024;12(3):512.

[8] Cai H, Ye T, Li D, et al. Epicardial and perirenal adipose tissue: emerging roles in chronic kidney disease progression. Front Med. 2021;8:781541.

审批编号：CN-161212

有效期至：2025-12-10

声明：仅供医疗卫生专业人士参考，不得转发或分享非医疗卫生专业人士。不得用于推广目的。本文的攥稿/发布由阿斯利康提供支持。